Acticor Biotech, a Paris, France-based biotechnology company focused on the treatment of acute ischemic stroke, raised €1.5M in funding.
CapDecisif Management made the investment.
Led by Gilles Avenard, CEO, Acticor Biotech is a bio-pharmaceutical company, spin-off of Inserm (U1148 – Bichat Hospital, Paris, France) dedicated to developing an innovative treatment in the therapy of acute ischemic stroke.
The company, which had already secured €1.4m in the first closing and has now raised €2.9m in total funding, will use the funds to continue to develop its lead candidate ACT-017 in Acute Ischemic Stroke, toward its entry in Phase I Clinical Trial.
Built upon the expertise of and the results of researches conducted by founders Dr. Martine Jandrot-Perrus and Dr Christian Gachet, in two INSERM units, and Professor Philippe Billiald at Paris-Sud University, Acticor Biotech recently signed an R&D Partnership Agreement with Mediolanum farmaceutici to co-finance research and development of ACT017.